Latest filingSep 09, 2026Most recent Form 4
TARS
Tarsus Pharmaceuticals, Inc.
Insider activity for last month from 08/09 to 09/09. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$160M5 sells
Net open-market-$160M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period5transactions
- S · Open-market sells · dominant5 · 100%
Activity by reported role
A joint filing can contribute to multiple roles5transactions
- CMO · dominant4 · 80%
- COO1 · 20%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeLin Elizabeth YeuCommon Stock · Indirect · By Spouse's Roth IRA
3,180Sep 04, 2026
Lin Elizabeth YeuCommon Stock · Direct
2,547Sep 04, 2026
Neervannan SeshadriCommon Stock · Direct
78,532Sep 04, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 09 → Sep 09
LessMore
Top insiders
By absolute net value across the selected period- LY-$1.2M
- NS-$387.9k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
No filing-only signal badges matched this period.
TARS transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| TARS | Lin Elizabeth Yeu | CMO | sale10b5-1 | 1.59k | -$14.3M | S | — | 0.0% | 09/09 | 09/04 |
| TARS | Lin Elizabeth Yeu | CMO | sale10b5-1 | 1.59k | -$13.5M | S | — | 0.0% | 09/09 | 09/04 |
| TARS | Lin Elizabeth Yeu | CMO | sale10b5-1 | 5.38k | -$48.4M | S | — | 0.0% | 09/09 | 09/04 |
| TARS | Lin Elizabeth Yeu | CMO | sale10b5-1 | 5.38k | -$45.7M | S | — | 0.0% | 09/09 | 09/04 |
| TARS | Neervannan Seshadri | COO | sale10b5-1 | 4.56k | -$38.7M | S | — | 0.0% | 09/09 | 09/04 |
Tarsus Pharmaceuticals, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Tarsus Pharmaceuticals, Inc.?
Lin Elizabeth Yeu, Neervannan Seshadri.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Lin Elizabeth Yeu reported a sale on Sep 04, 2026 valued at $14.3M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,608,825.00. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.